Galderma (SIX: GALD) today announced two-year data from a new interim analysis of a long-term extension study investigating the safety and efficacy of Nemluvio in moderate-to-severe atopic dermatitis. The data show that Nemluvio is well tolerated, with no new safety signals identified, reinforcing its rapid onset of action and demonstrating sustained and increased improvements in symptoms including itch and skin lesions with prolonged treatment up to two years.1 These data will be presented in ...

Juniper Networks, a leader in secure, AI-native networks, today announced that it has won two “Best of Show” awards at Interop Tokyo 2025, maintaining its impressive winning streak of continuous wins at the prestigious industry conference since 2007. The latest awards recognize Juniper’s commitment to ensuring an exceptional client-to-cloud operator and end-user experience through Juniper’s industry-leading Mist™ AI-native networking platform. Juniper received four awards across four categori...